Indication
Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.
Loading your page…
Loading your page…
Hyperphosphatemia
Marketing Authorisation Holder: Mitsubishi Pharma Europe Ltd
EMA Authorisation: 21/01/2013
INN: colestilan
AI Drug & Interaction Analysis
Free account required
Ask Osler about BindRen: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.